• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
×

Target

Host

Species Reactivity

Species Reactivity

Conjugate

Conjugate

ChromoTek FITC Plus-conjugated LAG3 VHH

FITC-lt targets LAG3 in FC and IF applications and shows reactivity with Human samples.

Host/Type

Alpaca VHH

Reactivity

Human

Applications

FC, IF

Conjugate

FITC Plus Fluorescent dye

Cat no : FITC-lt

Synonyms

LAG3-Nanobody, LAG3-single domain antibody (sdAb), CD223, FDC, LAG 3, LAG3, LAG-3, lymphocyte activation gene 3, Protein FDC

Validation Data Gallery

  • 1X10^6 HEK LAG3 transient transfected cells (red) and HEK parental cells were surface stained with 0.25 µg FITC Plus conjugated-LAG3 VHH (FITC-lt). Cells were not fixed.

    1X10^6 HEK LAG3 transient transfected cells (red) and HEK parental cells were surface stained with 0.25 µg FITC Plus conjugated-LAG3 VHH (FITC-lt). Cells were not fixed.

  • Live HeLa cells transfected with human LAG3 were immunostained FITC Plus conjugated-LAG3 VHH (FITC-lt, 1:500, green). Cells were fixed and nuclei were stained with DAPI (cyan). Epifluorescence images were acquired with a 20x objective and post-processed.  Note: Immunostaining with FITC-lt can also be performed after formaldehyde fixation of the cells.

    Live HeLa cells transfected with human LAG3 were immunostained FITC Plus conjugated-LAG3 VHH (FITC-lt, 1:500, green). Cells were fixed and nuclei were stained with DAPI (cyan). Epifluorescence images were acquired with a 20x objective and post-processed.  Note: Immunostaining with FITC-lt can also be performed after formaldehyde fixation of the cells.

  • Left: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated LAG-3 VHH (FITC-lt) and CL405 CD3 (CL405-65151). Right: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated LAG-3 VHH (FITC-lt) (red) or unstained (blue). 1X10^6 untreated human PBMCs were surface stained with 0.5ug FITC Plus conjugated LAG-3 VHH (FITC-lt) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were not fixed. Lymphocytes were gated.

    Left: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated LAG-3 VHH (FITC-lt) and CL405 CD3 (CL405-65151). Right: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated LAG-3 VHH (FITC-lt) (red) or unstained (blue). 1X10^6 untreated human PBMCs were surface stained with 0.5ug FITC Plus conjugated LAG-3 VHH (FITC-lt) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were not fixed. Lymphocytes were gated.

Product Information

FITC-lt targets LAG3 in FC and IF applications and shows reactivity with Human samples.

ApplicationsFC, IF
ReactivityHuman
ConjugateFITC Plus Fluorescent dye
Type Nanobody
ClassRecombinant
HostAlpaca
AffinityPicomolar range, below the assay limit (biolayer interferometry)
Molecular Weight15.141 kDa
FormLiquid
Excitation/Emission Maxima Wavelengths495 nm / 524 nm
RRIDAB_3101919
Storage Buffer500 mM NaCl, 10 mM HEPES pH 7.0, 5 mM EDTA, 0.09% sodium azide
Storage ConditionStore at -20°C; Shipped at ambient temperature.
BackgroundLAG-3, also known as CD223, is an immune checkpoint molecule that regulates both T-cell activation and homeostasis. LAG-3 is expressed on activated T cells, NK cells, regulatory T cells, and plasmacytoid dendritic cells. It is a CD4-related molecule that binds MHC class II. LAG-3 plays an important role in modulating T cell expansion and function, and blockade of LAG-3 with monoclonal antibodies can augment T cell function. (PMID: 15634887; 21086108; 28783703)